在补偿性肝硬化中对延长释放皮尔芬尼的非侵入性评估. 奥迪赛研究,一个随机试验
Linda E Muñoz-Espinosa1, Aldo Torre2, Laura Cisneros3
1Universidad Autónoma de Nuevo León, "Dr. José E. González" University Hospital, Monterrey, Mexico.
概括
延长释放皮尔芬尼 (PR-PFD) 每天1200毫克显著降低了24个月的补偿性肝硬化患者的肝纤维化标志物. 这种治疗还改善了肝功能,MELD得分和生活质量,没有安全问题.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 晚期肝纤维化 (ALF) 是慢性肝病中不良结果的关键预测因素.
- 目前的治疗方法侧重于病因学,突出了停止或逆转纤维化的战略的需要.
- 补偿性肝硬化代表了干预措施可以防止脱补偿的阶段.
研究的目的:
- 评估延长释放皮尔芬尼 (PR-PFD) 在补偿性肝硬化患者的疗效和安全性.
- 为了确定PR-PFD在治疗肝纤维化的最佳剂量.
- 评估PR-PFD对肝功能,疾病进展和生活质量的影响.
主要方法:
- 一项为期24个月的随机对照试验,涉及180名晚期肝纤维化患者 (F4).
- 参与者被分配接受安慰剂,1200毫克/天PR-PFD或1800毫克/天PR-PFD,以及标准护理.
- 定期监测包括实验室检测,肝硬度测量 (LSM),FibroTest,超声波和内镜.
主要成果:
- 与安慰剂和1800毫克/天组 (p < 0.001) 相比,每天1200毫克的PR-PFD组显示纤维化显著减少,根据LSM的估计.
- 在每天1200毫克的PR-PFD组中,纤维检测得分与基线相比显著下降 (p < 0.001).
- 在肝功能测试,MELD得分和生活质量方面观察到改善;在1200毫克/天组中,脱补偿事件较少发生.
结论:
- 1200 mg/天的PR-PFD有效降低了24个月的补偿性肝硬化中非侵入性肝纤维化标志物.
- 在这种剂量的PR-PFD治疗改善了肝功能,MELD得分和生活质量.
- 1200毫克/天的PR-PFD剂量在这个患者群体中显示出良好的安全性.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.6K
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019
7.7K
相关概念视频
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
62
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
62
01:09Methods for Studying Drug Absorption: In situ
191
In situ experiments, such as the Doluisio method and Single-Pass Perfusion technique, provide critical insights into drug uptake by simulating in vivo conditions for drug absorption.
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
191